ZBIO (Zenas BioPharma, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ZBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Christy J. Oliger | Director | A | — | — |
| 2026-06-17 | PATRICK G ENRIGHT | Director | A | — | — |
| 2026-06-17 | Lisa von Moltke | See Remarks | A | — | — |
| 2026-06-17 | Joseph L Farmer | See Remarks | A | — | — |
| 2026-06-17 | LEON O MOULDER JR | See Remarks | A | — | — |
| 2026-06-17 | Hongbo Lu | Director | A | — | — |
| 2026-06-17 | Patricia L Allen | Director | A | — | — |
| 2026-06-17 | JOHN J ORLOFF | Director | A | — | — |
| 2026-06-17 | Jennifer A. Fox | See Remarks | A | — | — |
| 2026-06-17 | Jason Raleigh Nunn | Director | A | — | — |
| 2026-06-17 | James P Boylan | Director | A | — | — |
| 2026-05-18 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2026-04-29 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2026-04-02 | Hongbo Lu | Director | Buy | — | — |
| 2026-04-01 | Fairmount Healthcare Fund II L.P. | Director | Buy | — | — |
| 2026-02-13 | Hongbo Lu | Director | Buy | — | — |
| 2026-02-13 | Patricia L Allen | Director | Buy | — | — |
| 2026-02-03 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2026-01-09 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2025-10-14 | PATRICK G ENRIGHT | Director | Buy | — | — |
| 2025-10-14 | Jason Raleigh Nunn | Director | Buy | — | — |
| 2025-10-14 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | Buy | — | — |
| 2025-10-09 | Peter Evan Harwin | Director | Buy | — | — |
| 2025-10-09 | LEON O MOULDER JR | See Remarks | Buy | — | — |
| 2025-10-09 | Hongbo Lu | Director | Buy | — | — |
| 2025-06-12 | Orlando Oliveira | See Remarks | A | — | — |
| 2025-06-12 | Joseph L Farmer | See Remarks | A | — | — |
| 2025-06-12 | PATRICK G ENRIGHT | Director | A | — | — |
| 2025-06-12 | Jennifer A. Fox | See Remarks | A | — | — |
| 2025-06-12 | Jason Raleigh Nunn | Director | A | — | — |
| 2025-06-12 | JOHN J ORLOFF | Director | A | — | — |
| 2025-06-12 | LEON O MOULDER JR | See Remarks | A | — | — |
| 2025-06-12 | Peter Evan Harwin | Director | A | — | — |
| 2025-06-12 | Patricia L Allen | Director | A | — | — |
| 2025-06-12 | James P Boylan | Director | A | — | — |
| 2025-06-12 | Hongbo Lu | Director | A | — | — |
| 2025-04-28 | Ting Xiao | Director | Buy | — | — |
| 2025-04-17 | Lisa von Moltke | See Remarks | A | — | — |
| 2025-02-19 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2025-02-11 | Ting Xiao | Director | Buy | — | — |
| 2024-12-18 | Orlando Oliveira | Chief Commercial Officer | A | — | — |
| 2024-12-18 | Jennifer A. Fox | See Remarks | A | — | — |
| 2024-12-04 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2024-11-20 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2024-09-20 | LEON O MOULDER JR | Chief Executive Officer | Buy | — | — |
| 2024-09-18 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%+ Owner | C | — | — |
| 2024-09-18 | Zebra Aggregator, LP | 10%+ Owner | MIXED | — | — |
| 2024-09-17 | Hongbo Lu | Director | Buy | — | — |
| 2024-09-17 | LEON O MOULDER JR | Chief Executive Officer | C | — | — |
| 2024-09-17 | Fairmount Healthcare Fund II L.P. | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,761,359 | — |
| — | Director | 2,359,025 | — |
| — | Director | 2,209,025 | — |
| — | Director | 1,844,659 | — |
| — | Director | 1,173,395 | — |
| — | 10%+ Owner | 1,173,395 | — |
| — | Director | 1,003,814 | — |
| — | 10%+ Owner | 669,061 | — |
| — | 10%+ Owner | 600,906 | — |
| — | See Remarks | 520,083 | — |
| — | Director | 426,736 | — |
| — | Director | 19,860 | — |
| — | Director | 10,000 | — |
| — | See Remarks | 1,592 | — |
| — | See Remarks | 974 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZBIO quote page; the site-wide leaderboard is on the insider transactions hub.